Diagnosis of Early Malignancy
Early detection of cancer through a screening program for healthy and high-risk individuals is a key application of liquid biopsy approaches. Current therapeutic strategies allow successful treatment of many patients if the disease is detected early enough. Whereas metastatic disease still remains incurable with very few exceptions (for example, small liver metastases in colon cancer). Liquid biopsy approaches based on DDX-Sentinel Technology may provide a new avenue for early cancer detection.
Another application for DDX-Sentinel liquid biopsy tests is to diagnose those cancers for which there is no biopsy material readily available or for which a tissue biopsy is indeterminate. In lung cancer, for example, tissue samples are not available or, if available, are indeterminate in up to 30% of patients. This highlights the medical need for liquid biopsy methods to assess tumor status.
Monitoring Therapeutic Response
Serial liquid biopsy analyses during the course of treatment may give insight into how a patient is responding to therapy. Our DDX-Sentinel cancer tests may complement or improve the monitoring of therapeutic response, which is orthogonal to current approaches, and may offer an additional objective parameter that may improve current clinical cancer management algorithms.
Monitoring Disease Recurrence
In patients who appear to have achieved a complete response to treatment, liquid biopsy may provide improved monitoring of tumor recurrence and assessment of minimal residue disease. Monitoring post treatment is an important application, as more than 95% of all cancer deaths worldwide happen after relapse. Based on this, it is very important to detect relapse at the earliest possible time and monitor recurrence in a noninvasive way avoiding painful or dangerous invasive methods. More frequent intervals for cancer detection with DDX-Sentinel cancer tests can help physicians manage patients and prompt a change in therapy or the acceleration of diagnostic modalities.
Monitoring is desirable following initial diagnosis and therapy selection for assessing tumor growth, metastases or resistance. This monitoring takes place during the course of therapy and allows physicians to adjust therapy based on the changing genetic profile of the tumor. The emergence of targeted drugs for treating patients with specific mutations means that liquid biopsy diagnostics such as, DDX-Sentinel Sequencing, can identify druggable mutations for which treatment options can positively affect patient outcomes.